Oral Cavity Squamous Cell Carcinoma
Associated Genetic Biomarkers
NCI Definition: A squamous cell carcinoma arising from the oral cavity. It affects predominantly adults in their fifth and sixth decades of life and is associated with alcohol and tobacco use. Human papillomavirus is present in approximately half of the cases. It is characterized by a tendency to metastasize early to the lymph nodes. When the tumor is small, patients are often asymptomatic. Physical examination may reveal erythematous or white lesions or plaques. The majority of patients present with signs and symptoms of locally advanced disease including mucosal ulceration, pain, difficulty with speaking, chewing, and swallowing, bleeding, weight loss, and neck swelling. Patients may also present with swollen neck lymph nodes without any symptoms from the oropharyngeal tumor. The most significant prognostic factors are the size of the tumor and the lymph nodes status. 
Oral cavity squamous cell carcinomas most frequently harbor alterations in TP53, CDKN2A, NOTCH1, PIK3CA, and KMT2D .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 c.142-c.212 Missense, TP53 c.1-c.137 Missense, and TP53 Missense are the most common alterations in oral cavity squamous cell carcinoma .
There are 17 clinical trials for oral cavity squamous cell carcinoma, of which 16 are open and 1 is completed or closed. Of the trials that contain oral cavity squamous cell carcinoma as an inclusion criterion, 2 are early phase 1 (1 open), 3 are phase 1 (3 open), 4 are phase 1/phase 2 (4 open), 6 are phase 2 (6 open), and 2 are phase 3 (2 open).
ERBB2 is the most frequent gene inclusion criterion for oral cavity squamous cell carcinoma clinical trials .
Placebo, cxc chemokine receptor 2 antagonist azd5069, and hyperbaric oxygen (substance) are the most common interventions in oral cavity squamous cell carcinoma clinical trials.
Significant Genes in Oral Cavity Squamous Cell Carcinoma
ERBB2 is mutated in 2.5% of oral cavity squamous cell carcinoma patients .
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for oral cavity squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and oral cavity squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
Cxc chemokine receptor 2 antagonist azd5069, medi-4736, and stat3 antisense oligonucleotide isis 481464 are the most frequent therapies in oral cavity squamous cell carcinoma trials with ERBB2 mutations as inclusion criteria .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.